1-Propoxynonane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Propoxynonane
• 化学式: C₁₂H₂₆O
• 分子量: 186.33
• InChiKey: RCRBXFZNEXKMOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  13
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Catalytic alkylation of alcohols to liquid ethers and organic compounds to alkylated products
  申请人：Carter Melvin Keith

  公开号：US20130204037A1

  公开（公告）日：2013-08-08

  A catalytic process is taught for non-oxidative alkylation of organic compounds, comprising alcohols, alkanes, glycols, ethers, aldehydes, ketones, carboxylic acids, esters, amines, thiols or phosphines, by alkyl groups produced from alcohols or glycols, forming products comprising ethers and other higher molecular weight alkylated compounds. The process is conducted at a reflux temperature below 200° C. in the presence of an acid, alkali or neutral salt dehydrating agent comprising sulfuric acid, phosphoric acid or their salts, lime or anhydrous calcium sulfate in the absence of zero valent metals and air. Specifically, this catalytic process converts ethanol to ethyl butyl ethers, ethyl hexyl ethers and dibutyl ethers or oxygenated gasoline as well as amines comprising n-butyl amine plus butanol to dibutyl amine and butyl hexyl amines at ambient pressure. This same catalytic alkylation chemistry, which does not constitute a condensation reaction, alkylates 4-hydroxybenzoic acid using ethanol to 4-ethoxyethylbenzoic acid products.

  本发明教授一种非氧化烷基化有机化合物的催化过程，包括醇、烷烃、乙二醇、醚、醛、酮、羧酸、酯、胺、硫醇或膦化物，通过从醇或乙二醇产生的烷基基团进行烷基化反应，形成包括醚和其他高分子量烷基化合物的产物。该过程在200°C以下的回流温度下，在没有零价金属和空气的情况下，存在酸、碱或中性盐脱水剂，包括硫酸、磷酸或它们的盐、石灰或无水硫酸钙。具体而言，该催化过程将乙醇转化为乙基丁基醚、乙基己基醚和二丁基醚或含氧汽油，以及在常压下将正丁胺和丁醇烷基化为二丁基胺和正丁己胺。这种催化烷基化化学反应还可以使用乙醇将4-羟基苯甲酸烷基化为4-乙氧基乙基苯甲酸产物，不构成缩合反应。
• [EN] POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA<br/>[FR] POLYNUCLÉOTIDES CODANT POUR LA LIPOPROTÉINE LIPASE DESTINÉS AU TRAITEMENT DE L'HYPERLIPIDÉMIE
  申请人：MODERNATX INC

  公开号：WO2017201333A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of hyperlipidemia. mRNAs for use in the invention, when administered in vivo, encode human lipoprotein lipase (LPL), isoforms thereof, functional fragments thereof, and fusion proteins comprising LPL. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto, mRNA therapeaies of the invention increase and/or restore deficient levels of LPL expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of triglycerides associated with deficient LPL activity in subjects.

  该发明涉及mRNA疗法用于治疗高脂血症。该发明中使用的mRNA，在体内给予时，编码人类脂蛋白脂肪酶（LPL）、其异构体、其功能性片段以及包含LPL的融合蛋白。该发明中的mRNA最好被封装在脂质纳米颗粒（LNPs）中，以实现对受试者的细胞和/或组织的高效传递，当给予治疗时，该发明中的mRNA疗法增加和/或恢复受试者中LPL表达和/或活性的不足水平。该发明中的mRNA疗法进一步降低与受试者中LPL活性不足相关的甘油三酯水平。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。
• Compounds exhibiting thrombopoietin receptor agonism
  申请人：Takayama Masami

  公开号：US20070043087A1

  公开（公告）日：2007-02-22

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  化合物的一般式(I)表示的复合物，其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。这是一个前药、药物可接受的盐或其溶剂。
• Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same
  申请人：MITSUI TOATSU CHEMICALS, INCORPORATED

  公开号：EP0751133A1

  公开（公告）日：1997-01-02

  The present invention relates to a novel pyrimidine compound represented by the following Formulas (1) and (2). These compounds are useful as components for liquid crystal compositions, and a liquid crystal composition containing the compound of the present invention provides a liquid crystal element having excellent characteristics such as high speed response, orientation and high contrast ratio. wherein R1 and R2 each represent a linear or branched alkyl group, alkoxyl group having 1 to 24 carbon atoms, or a linear or branched alkenyl group or alkenyloxy group having 2 to 24 carbon atoms each of which may be substituted; R3 and R4 each represent a linear or branched alkyl group or alkenyl group having 3 to 24 carbon atoms each of which may be substituted; A1 and A2 each represent a substituted or unsubstituted 1,4-phenylene group, a pyridine-2,5-diyl group or a trans-1,4-cyclohexylene group; X1 and X2 each represent a single bond, a -COO- group, a -OCO- group, a -OCH2- group or a -CH2O- group; Y1 and Y2 each represent a -COO- group or a -OCO- group; and a, b, p, q, m and n each represent 0 or 1, provided that a + b + p + q is not 0.

  本发明涉及由以下式子（1）和（2）代表的新型嘧啶化合物。这些化合物可用作液晶组合物的成分，含有本发明化合物的液晶组合物可提供具有高速响应、定向和高对比度等优异特性的液晶元件。 其中 R1 和 R2 分别代表具有 1 至 24 个碳原子的直链或支链烷基、烷氧基或具有 2 至 24 个碳原子的直链或支链烯基或烯氧基，其中每个基团都可以被取代；R3 和 R4 分别代表具有 3 至 24 个碳原子的直链或支链烷基或烯基，其中每个基团都可以被取代；A1和A2各自代表取代或未取代的1,4-亚苯基、吡啶-2,5-二基或反式-1,4-环己烯基； X1和X2各自代表单键、-COO-基团、-OCO-基团、-OCH2-基团或-CH2O-基团；Y1和Y2各自代表一个-COO-基团或一个-OCO-基团；以及a、b、p、q、m和n各自代表0或1，条件是a + b + p + q不为0。